Drugs that contain Brimonidine Tartrate
1. Drug name - ALPHAGAN P
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8858961 | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Sep, 2023
(11 months from now) | |
|
US8858961
(Pediatric) | ALLERGAN | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 5 months from now) | |
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.1% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
2. Drug name - LUMIFY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(7 years from now) | |
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(7 years from now) | |
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.025% | SOLUTION/DROPS;OPHTHALMIC | Over the counter |
3. Drug name - MIRVASO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(1 year, 7 months from now) | |
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(2 years from now) | |
| US8410102 | GALDERMA LABS LP | Methods and compositions for treating or preventing erythema |
May, 2025
(2 years from now) | |
| US8231885 | GALDERMA LABS LP | Compounds, formulations, and methods for ameliorating telangiectasis |
May, 2025
(2 years from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(2 years from now) | |
| US9861631 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US9861632 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US8513249 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US8513247 | GALDERMA LABS LP | Methods and compositions for safe and effective treatment of erythema |
Mar, 2031
(8 years from now) | |
| US8163725 | GALDERMA LABS LP | Gel compositions and methods of use |
Jun, 2031
(8 years from now) | |
| US10201517 | GALDERMA LABS LP | Brimonidine gel compositions and methods of use |
Jun, 2031
(8 years from now) | |
| US8053427 | GALDERMA LABS LP | Brimonidine gel composition |
Jun, 2031
(8 years from now) | |
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.33% BASE | GEL;TOPICAL | Prescription |
4. Drug name - QOLIANA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265117 | SANDOZ INC | Topical brimonidine tartrate formulations that lack chlorine dioxide |
Aug, 2025
(2 years from now) | |
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 0.15% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.